Logo image of OBLN

Obalon Therapeutics Inc (OBLN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OBLN -

3.05
-0.19 (-5.86%)
Last: 6/15/2021, 8:00:01 PM
3.12
+0.07 (+2.3%)
After Hours: 6/15/2021, 8:00:01 PM
Fundamental Rating

2

Overall OBLN gets a fundamental rating of 2 out of 10. We evaluated OBLN against 186 industry peers in the Health Care Equipment & Supplies industry. While OBLN seems to be doing ok healthwise, there are quite some concerns on its profitability. OBLN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • OBLN had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -64.81%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -1387.25%
PM (TTM) -1391.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

  • OBLN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

  • OBLN has an Altman-Z score of -14.40. This is a bad value and indicates that OBLN is not financially healthy and even has some risk of bankruptcy.
  • There is no outstanding debt for OBLN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.4
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

  • OBLN has a Current Ratio of 1.86. This is a normal value and indicates that OBLN is financially healthy and should not expect problems in meeting its short term obligations.
  • OBLN has a Quick Ratio of 1.86. This is a normal value and indicates that OBLN is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.86

More info and screens

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 76.15% over the past year.
  • The Revenue for OBLN has decreased by -64.65% in the past year. This is quite bad
  • OBLN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.03% yearly.
EPS 1Y (TTM)76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.43%
Revenue 1Y (TTM)-64.65%
Revenue growth 3Y-45.69%
Revenue growth 5Y-17.03%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.38% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 369.34% on average over the next years. This is a very strong growth
EPS Next Y43.12%
EPS Next 2Y29.83%
EPS Next 3Y22.16%
EPS Next 5Y17.38%
Revenue Next Year953.33%
Revenue Next 2Y274.17%
Revenue Next 3Y334.11%
Revenue Next 5Y369.34%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OBLN Yearly Revenue VS EstimatesOBLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
OBLN Yearly EPS VS EstimatesOBLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • OBLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBLN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBLN Price Earnings VS Forward Price EarningsOBLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.11
OBLN Per share dataOBLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as OBLN's earnings are expected to grow with 22.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.83%
EPS Next 3Y22.16%

More info and screens

0

5. Dividend

5.1 Amount

  • OBLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Obalon Therapeutics Inc

NASDAQ:OBLN (6/15/2021, 8:00:01 PM)

After market: 3.12 +0.07 (+2.3%)

3.05

-0.19 (-5.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)03-11
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners45.04%
Ins Owner Change0%
Market Cap30.57M
Revenue(TTM)808.00K
Net Income(TTM)-11.24M
Analysts0
Price Target18.82 (517.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.83
P/FCF N/A
P/OCF N/A
P/B 3.03
P/tB N/A
EV/EBITDA -2.11
EPS(TTM)-3.17
EYN/A
EPS(NY)-1.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.08
BVpS1.01
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -1387.25%
PM (TTM) -1391.09%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.86
Altman-Z -14.4
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.43%
EPS Next Y43.12%
EPS Next 2Y29.83%
EPS Next 3Y22.16%
EPS Next 5Y17.38%
Revenue 1Y (TTM)-64.65%
Revenue growth 3Y-45.69%
Revenue growth 5Y-17.03%
Sales Q2Q%-100%
Revenue Next Year953.33%
Revenue Next 2Y274.17%
Revenue Next 3Y334.11%
Revenue Next 5Y369.34%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Obalon Therapeutics Inc / OBLN FAQ

What is the fundamental rating for OBLN stock?

ChartMill assigns a fundamental rating of 2 / 10 to OBLN.


What is the valuation status of Obalon Therapeutics Inc (OBLN) stock?

ChartMill assigns a valuation rating of 2 / 10 to Obalon Therapeutics Inc (OBLN). This can be considered as Overvalued.


Can you provide the profitability details for Obalon Therapeutics Inc?

Obalon Therapeutics Inc (OBLN) has a profitability rating of 1 / 10.


Can you provide the financial health for OBLN stock?

The financial health rating of Obalon Therapeutics Inc (OBLN) is 2 / 10.